microRNA-133 inhibits cell proliferation, migration and invasion in prostate cancer cells by targeting the epidermal growth factor receptor

Oncology Reports

Volumn 27, Issue 6, 2012, Pages 1967-1975

  Tao, Jun ^a   Wu, Deyao ^b   Xu, Bin ^c   Qian, Weichun ^d   Li, Pengchao ^a   Lu, Qiang ^a   Yin, Changjun ^a   Zhang, Wei ^a  

^a NANJING MEDICAL UNIVERSITY   (China)

^b NANTONG MEDICAL COLLEGE   (China)

^c SOUTHEAST UNIVERSITY   (China)

^d NANJING MEDICAL UNIVERSITY   (China)

Author keywords

Epidermal growth factor receptor; miR 133; Prostate cancer

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; LUCIFERASE; MICRORNA; MICRORNA 133A; MICRORNA 133B; UNCLASSIFIED DRUG;

ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CANCER CELL CULTURE; CELL ASSAY; CELL INVASION; CELL VIABILITY; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFECT; DRUG MECHANISM; ENZYME ASSAY; GENE EXPRESSION REGULATION; GENE FUNCTION; GENETIC TRANSFECTION; IN VITRO STUDY; MIGRATION INHIBITION; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN TARGETING; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; DEAD-BOX RNA HELICASES; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MICRORNAS; NEOPLASM INVASIVENESS; PROSTATIC NEOPLASMS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RIBONUCLEASE III; RNA INTERFERENCE; RNA, SMALL INTERFERING;

EID: 84860757028     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2012.1711     Document Type: Article

References (21)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J and Thun MJ: Cancer statistics, 2009. CA Cancer J Clin 59: 225-249, 2009.
2. Pashayan N, Pharoah P, Neal DE, et al: Stage shift in PSA-detected prostate cancers - effect modification by Gleason score. J Med Screen 16: 98-101, 2009.
3. Mottet N, Bellmunt J, Bolla M, et al: EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol 59: 572-583, 2011.
4. Wang L, Tang H, Thayanithy V, et al: Gene networks and microRNAs implicated in aggressive prostate cancer. Cancer Res 69: 9490-9497, 2009.
5. Traish AM and Morgentaler A: Epidermal growth factor receptor expression escapes androgen regulation in prostate cancer: a potential molecular switch for tumour growth. Br J Cancer 101: 1949-1956, 2009.
6. Cohen MB and Rokhlin OW: Mechanisms of prostate cancer cell survival after inhibition of AR expression. J Cell Biochem 106: 363-371, 2009.
7. Porkka KP, Pfeiffer MJ, Waltering KK, Vessella RL, Tammela TL and Visakorpi T: microRNA expression profiling in prostate cancer. Cancer Res 67: 6130-6135, 2007. (Pubitemid 47037493)
8. Tong AW, Fulgham P, Jay C, et al: microRNA profile analysis of human prostate cancers. Cancer Gene Ther 16: 206-216, 2009.
9. Ambs S, Prueitt RL, Yi M, et al: Genomic profiling of microRNA and messenger RNA reveals deregulated microRNA expression in prostate cancer. Cancer Res 68: 6162-6170, 2008.
10. Rao PK, Missiaglia E, Shields L, et al: Distinct roles for miR-1 and miR-133a in the proliferation and differentiation of rhabdomyosarcoma cells. FASEB J 24: 3427-3437, 2010.
11. Rao PK, Kumar RM, Farkhondeh M, Baskerville S and Lodish HF: Myogenic factors that regulate expression of muscle-specific microRNAs. Proc Natl Acad Sci USA 103: 8721-8726, 2006. (Pubitemid 43878086)
12. Bostjancic E, Zidar N, Stajer D and Glavac D: microRNAs miR-1, miR-133a, miR-133b and miR-208 are dysregulated in human myocardial infarction. Cardiology 115: 163-169, 2010.
13. Yoshino H, Chiyomaru T, Enokida H, et al: The tumour-suppressive function of miR-1 and miR-133a targeting TAGLN2 in bladder cancer. Br J Cancer 104: 808-818, 2011.
14. Uchida Y, Chiyomaru T, Enokida H, et al: miR-133a induces apoptosis through direct regulation of GSTP1 in bladder cancer cell lines. Urol Oncol: Mar 9, 2011 (Epub ahead of print).
15. Kano M, Seki N, Kikkawa N, et al: miR-145, miR-133a and miR-133b: tumor suppressive miRNAs target FSCN1 in esophageal squamous cell carcinoma. Int J Cancer 127: 2804-2814, 2010.
16. Neto AS, Tobias-Machado M, Wroclawski ML, Fonseca FL, Pompeo AC and Del Giglio A: Molecular oncogenesis of prostate adenocarcinoma: role of the human epidermal growth factor receptor 2 (HER-2/neu). Tumori 96: 645-649, 2010.
17. Wong TS, Liu XB, Chung-Wai Ho A, Po-Wing Yuen A, Wai-Man Ng R and Ignace Wei W: Identification of pyruvate kinase type M2 as potential oncoprotein in squamous cell carcinoma of tongue through microRNA profiling. Int J Cancer 123: 251-257, 2008.
18. Kim HG, Kassis J, Souto JC, Turner T and Wells A: EGF receptor signaling in prostate morphogenesis and tumorigenesis. Histol Histopathol 14: 1175-1182, 1999.
19. Hernes E, Fossa SD, Berner A, Otnes B and Nesland JM: Expression of the epidermal growth factor receptor family in prostate carcinoma before and during androgen-independence. Br J Cancer 90: 449-454, 2004. (Pubitemid 38250644)
20. Kharait S, Dhir R, Lauffenburger D and Wells A: Protein kinase Cdelta signaling downstream of the EGF receptor mediates migration and invasiveness of prostate cancer cells. Biochem Biophys Res Commun 343: 848-856, 2006.
21. Gan Y, Shi C, Inge L, Hibner M, Balducci J and Huang Y: Differential roles of ERK and Akt pathways in regulation of EGFR-mediated signaling and motility in prostate cancer cells. Oncogene 29: 4947-4958, 2010.